Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis

• Published in: Molecular cytogenetics Vol. 4; no. 1; p. 25
• Main Authors: Kolquist, Kathryn A, Schultz, Roger A, Slovak, Marilyn L, McDaniel, Lisa D, Brown, Theresa C, Tubbs, Raymond R, Cook, James R, Theil, Karl S, Cawich, Victoria, Valentin, Caitlin, Minier, Sara, Neill, Nicholas J, Byerly, Steve, Morton, S Annie, Sahoo, Trilochan, Ballif, Blake C, Shaffer, Lisa G
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 16.11.2011; BioMed Central; BMC
• Subjects: Analysis; Apoptosis; Arrays; Cancer; Cell cycle; chromosome aberration; Chromosomes; Chronic lymphocytic leukemia; Cytogenetics; DNA microarrays; FISH; Fluorescence; Genes; Genomes; Genomics; Laboratories; Lymphoma; microarray; oligonucleotide; Prognosis
• ISSN: 1755-8166; 1755-8166
• DOI: 10.1186/1755-8166-4-25

Cytogenetic evaluation is a key component of the diagnosis and prognosis of chronic lymphocytic leukemia (CLL). We performed oligonucleotide-based comparative genomic hybridization microarray analysis on 34 samples with CLL and known abnormal karyotypes previously determined by cytogenetics and/or fluorescence in situ hybridization (FISH). Using a custom designed microarray that targets >1800 genes involved in hematologic disease and other malignancies, we identified additional cryptic aberrations and novel findings in 59% of cases. These included gains and losses of genes associated with cell cycle regulation, apoptosis and susceptibility loci on 3p21.31, 5q35.2q35.3, 10q23.31q23.33, 11q22.3, and 22q11.23. Our results show that microarray analysis will detect known aberrations, including microscopic and cryptic alterations. In addition, novel genomic changes will be uncovered that may become important prognostic predictors or treatment targets for CLL in the future.